FirstWord Pharma in its “Pricing Transparency in Pharma” report explores the rising demand for increased transparency.
The report highlights 10 key issues “pharma needs to understand and respond to,” and includes insights from experts in the field.
“Concerned that confidential pricing arrangements are more about profit than patient access, advocates see increasing price transparency as key to lowering costs and increasing patient access,” a description of the report states. “But drug pricing is complex and, at a market level, is nuanced by a range of regulatory, HTA and market access impacts.”
To learn more about this report, click here.